Department of Food Science and Nutrition, Wroclaw Medical University, ul. Borowska 211, 50-556 Wroclaw Poland.
Diagnostics Laboratory for Teaching and Research, Wroclaw Medical University, ul. Borowska 211, 50-556 Wroclaw, Poland.
J Trace Elem Med Biol. 2018 Jan;45:78-84. doi: 10.1016/j.jtemb.2017.09.024. Epub 2017 Sep 28.
Disturbed redox status may be critical to lung cancerogenesis, however little research has been conducted on general changes in total redox status in lung cancer. Levels and activities of antioxidants, especially enzymatic ones, are related to trace element concentration. Trace element status is often disturbed in cancers, however no studies concerning the association between redox and trace element status have been performed for lung cancer. We hypothesized that disturbed redox status in lung cancer patients is partially determined by trace elements while their distribution amongst blood compartments may differ compared to healthy subjects. Blood samples from lung cancer patients (n=44) and control subjects (n=44) were collected to assess redox and trace element status. Serum and whole blood Cu and Mn levels were determined with GF-AAS, and Zn-with F-AAS. In serum the total antioxidant status (TAS) was determined with the commercial kit TAS (Randox, UK), total oxidant status (TOS) was determined based on the method developed by Erel and the oxidative stress index (OSI) was calculated. Total protein (T-Prot), albumin (Alb), uric acid (UA) and total bilirubin (T-Bil) concentrations were measured with an auto-analyser (Konelab 20i, Thermoscientific, USA), SOD and CAT activity - with commercially available kits (Cayman, USA). The level of TAS, T-Prot, Alb, T-Bil, the activity of SOD, the concentration of whole blood Mn as well as serum and whole blood Zn were lower while TOS, OSI, serum Cu levels and serum Cu:Zn ratios were higher in lung cancer patients compared to the control group. In the lung cancer group TAS correlated positively with Alb and UA, serum Zn and negatively with whole blood Mn. Additionally, SOD positively correlated with the whole blood Mn and Cu:Zn ratio, while CAT - negatively with the whole blood Cu:Zn ratio. In the lung cancer sub-group at clinical stage I-II, TOS additionally negatively correlated with whole blood Zn, and CAT negatively with serum Cu and Cu:Zn ratio. In advanced lung cancer, we found a positive correlation between TAS and serum Zn, and a negative one - with serum Cu:Zn ratio. We observed a similar correlation between endogenous non-enzymatic antioxidants and TAS in the control group, however considerably fewer correlations between trace elements and antioxidants were observed. This study supports the hypothesis that disturbed redox status in lung cancer patients is linked with alterations in trace element status regarding Zn, Mn and Cu. Moreover, the type of biological fluid influences both - alterations in the metal profile and relationships with redox status parameters.
氧化还原状态的紊乱可能对肺癌的发生起着关键作用,但目前针对肺癌患者总体氧化还原状态的变化,相关研究仍较少。抗氧化剂的水平和活性,尤其是酶类抗氧化剂,与微量元素浓度有关。癌症患者的微量元素状态通常会紊乱,但目前尚未有研究针对肺癌患者的氧化还原状态和微量元素状态之间的关联进行探讨。我们假设肺癌患者的氧化还原状态紊乱部分是由微量元素决定的,而它们在血液中的分布可能与健康受试者不同。我们收集了 44 例肺癌患者和 44 例对照者的血液样本,以评估氧化还原和微量元素状态。用 GF-AAS 测定血清和全血的 Cu 和 Mn 水平,用 F-AAS 测定 Zn 水平。在血清中,用商业试剂盒 TAS(Randox,英国)测定总抗氧化状态(TAS),根据 Erel 开发的方法测定总氧化状态(TOS),并计算氧化应激指数(OSI)。用自动分析仪(Konelab 20i,Thermoscientific,美国)测定总蛋白(T-Prot)、白蛋白(Alb)、尿酸(UA)和总胆红素(T-Bil)浓度,用市售试剂盒(Cayman,美国)测定 SOD 和 CAT 活性。与对照组相比,肺癌患者的 TAS、T-Prot、Alb、T-Bil、SOD 活性、全血 Mn 浓度以及血清和全血 Zn 水平更低,而 TOS、OSI、血清 Cu 水平和血清 Cu:Zn 比值更高。在肺癌组中,TAS 与 Alb 和 UA 呈正相关,与全血 Mn 呈负相关。此外,SOD 与全血 Mn 和 Cu:Zn 比值呈正相关,而 CAT 与全血 Cu:Zn 比值呈负相关。在临床分期 I-II 的肺癌亚组中,TOS 与全血 Zn 呈负相关,CAT 与血清 Cu 和 Cu:Zn 比值呈负相关。在晚期肺癌中,我们发现 TAS 与血清 Zn 呈正相关,与血清 Cu:Zn 比值呈负相关。在对照组中,我们观察到内源性非酶抗氧化剂与 TAS 之间存在类似的相关性,但观察到的微量元素与抗氧化剂之间的相关性要少得多。这项研究支持这样一种假设,即肺癌患者的氧化还原状态紊乱与 Zn、Mn 和 Cu 等微量元素状态的改变有关。此外,生物液的类型会同时影响金属谱的改变和与氧化还原状态参数的关系。